Explore

Trendline Trendline
FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Rollout

FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Rollout

FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Rollout
Trendline Trendline
Eisai and Biogen's Subcutaneous Alzheimer's Drug Faces FDA Review Delay, Affecting Market Strategy

Eisai and Biogen's Subcutaneous Alzheimer's Drug Faces FDA Review Delay, Affecting Market Strategy

Eisai and Biogen's Subcutaneous Alzheimer's Drug Faces FDA Review Delay, Affecting Market Strategy
Trendline Trendline
FDA Delays Decision on Subcutaneous Leqembi for Alzheimer's by Three Months

FDA Delays Decision on Subcutaneous Leqembi for Alzheimer's by Three Months

FDA Delays Decision on Subcutaneous Leqembi for Alzheimer's by Three Months
Trendline Trendline
FDA Extends Review Period for Biogen and Eisai's Subcutaneous Alzheimer's Therapy

FDA Extends Review Period for Biogen and Eisai's Subcutaneous Alzheimer's Therapy

FDA Extends Review Period for Biogen and Eisai's Subcutaneous Alzheimer's Therapy
Trendline Trendline
FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change

FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change

FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change
Trendline Trendline
Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway
Trendline Trendline
Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone
Trendline Trendline
Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment

Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment

Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment
Trendline Trendline
Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion
Trendline Trendline
Life Sciences Companies Invest in Longevity Research to Extend Healthspan

Life Sciences Companies Invest in Longevity Research to Extend Healthspan

Life Sciences Companies Invest in Longevity Research to Extend Healthspan
Trendline Trendline
Pfizer and Eli Lilly Report Q1 Earnings Amidst FDA Leadership Changes

Pfizer and Eli Lilly Report Q1 Earnings Amidst FDA Leadership Changes

Pfizer and Eli Lilly Report Q1 Earnings Amidst FDA Leadership Changes
Trendline Trendline
Viridian Therapeutics' New Phase 3 Data Boosts Prospects for Thyroid Eye Disease Drug

Viridian Therapeutics' New Phase 3 Data Boosts Prospects for Thyroid Eye Disease Drug

Viridian Therapeutics' New Phase 3 Data Boosts Prospects for Thyroid Eye Disease Drug